About the Editors
David Sulzer, PhD, Columbia University, NY, New York, USA
Dr. David Sulzer is a neuroscientist and Professor of Neurobiology in Psychiatry, Neurology and Pharmacology at Columbia University Medical Center (CUMC), as well as the coordinator of the postdoctoral training program in basic neuroscience at Columbia. He is a member of the Parkinson’s Disease Foundation Research Center at Columbia and is a member of the Foundation’s Scientific Advisory Board. His lab explores synaptic connections that underlie learning as well as neurodegenerative diseases that occur at these synapses. In particular, they examine three-part synapses formed by excitatory cortical projections and modulatory midbrain dopamine projections that converge onto striatal neuron dendrites, resulting in the so-called striatal microcircuit, a.k.a. synaptic triad. Changes in the state of this structure underlie behavioral reinforcement or "reward" including that associated with food, sex, and motor learning. The synapses are also the primary targets for reinforcement by drugs of abuse including cocaine, amphetamine, nicotine, and opiates. Alterations in the state of the synapses appear to underlie addiction and schizophrenic psychosis, while loss of the participating neurons causes Parkinson's and Huntington’s diseases. His laboratory introduced the mechanism of action by which amphetamine works, developed the first methods to directly measure synaptic vesicle release of neurotransmitter from central synapses and the first means to optically measure neurotransmission, and has introduced new hypotheses of neurodegeneration in Parkinson's disease and habit learning. In 2017, the Sulzer laboratory introduced the role of autoimmune response in Parkinson’s disease patients, which answers a century-old mystery on the role of immune system activation in that disorder. Additionally, the Sulzer lab has published over 140 papers on this research. Dr. Sulzer has received various honorable awards from the McKnight, Helmsely, Picower, Simons, HDSA, and Michael J. Fox Foundations, the National Institute on Drug Abuse, NIH, and NARSAD.
K. Ray Chaudhuri, MD FRCP DSc, King's College London, London, UK
Dr. K. Ray Chaudhuri is a Professor of Neurology/Movement Disorders and Consultant Neurologist at King’s College Hospital and King’s College London, and also Medical Director of the National Parkinson Foundation International Centre of Excellence and Principal Investigator at the Maurice Wohl Clinical Neuroscience Institute and NIHR biomedical research centre at the Institute of Psychiatry. His major research interests are non-motor symptoms and continuous drug delivery treatments of PD, restless legs syndrome, sleep problems in PD, and parkinsonism in minority ethnic groups. He sits on several chairs and committees including the Nervous Systems Committee of the UK Dept. of Health, NIH Research, Chairman of the appointments/liaison committee of the Movement Disorders Society (2009–2013), where he is currently co-Chair, and Chairman of the newly-formed MDS Non-motor Study Group. He has served as a member of the scientific programme committee of the MDS (2013–2017), and in a task force of the practice parameter group for PD and RLS, EBM for non-motor symptoms of PD, and more recently Non-motor Symptoms of Parkinson’s, American Academy of Neurology. Other committee positions include MDS, advisor to NICE UK and the European Parkinson’s Disease Association. He serves in the Clinical Advisory Group of Parkinson’s UK. Other editorial responsibilities include being European Editor of Basal Ganglia and being part of the editorial board of Journal of Parkinson’s Disease. He is also the chief editor of the first comprehensive textbook on non-motor aspects of Parkinson’s, and was the recipient of the BMA book prize commendation prize. He represents UK research and development in NIH Research, as well as at a local level for London South CLRN neurosciences. Professor Chaudhuri is the author of 330 papers including reviews, book chapters, is co-editor of four books on PD and restless legs syndrome, and has published over 250 peer-reviewed abstracts. He was awarded the DSc degree by the University of London (2005), and is currently leading a 54 chapter, two-volume textbook on non-motor aspects of PD with Nataliya Titova, MD, PhD.
Stanley Fahn, MD, Columbia University, NY, New York USA
Stanley Fahn, MD is the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University. He has participated in clinical trials of many pharmacotherapeutic agents for PD. He developed a clinical trial to study the effect of levodopa therapy on the natural history of PD, which is funded by NIH. He co-directed the first controlled surgical trial for fetal tissue transplantation for patients with advanced PD. He has co-edited a number of volumes related to PD, dystonia, myoclonus and other movement disorders. Along with Dr. Ira Shoulson, Dr. Fahn was a co-founder of the Parkinson Study Group (PSG), a consortium of clinical investigators dedicated to conduct controlled clinical trials on the prevention and treatment of Parkinson's disease. He was co-principal investigator or Steering Committee member of several PSG multi center controlled clinical trials: DATATOP evaluated antioxidant agents in the early stages of the disease; trials testing lazabemide, a specific reversible MAO B inhibitor, in early PD; trials testing pramipexole, a dopamine agonist, in early PD and many more.
Stephanie Cragg, MA DPhil, Professor of Neuroscience, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
Professor Stephanie Cragg’s laboratory focuses on understanding dopamine neurotransmission in the basal ganglia, control by striatal circuits, and dysfunction in neurodegenerative disorders and drug addiction. Steph works at the forefront of understanding neuronal signalling dynamics in relation to the biology of neurodegenerative disease and addiction. Her research explores the regulation of neurons throughout the region of the brain termed basal ganglia, including understanding the function and dysfunction of the dopaminergic neurons which die off in Parkinson's. They are the founding group of the Oxford Parkinson's Disease Centre. Her first degree was in Natural Sciences at the University of Cambridge, and her DPhil explored neuronal dendrite function at the University of Oxford and New York University as a Mary Goodger Scholar. During Junior Research Fellowships and a Beit Memorial Fellowship in Oxford, and further research at NYU and the University of North Carolina, Dr. Cragg developed her expertise in real-time electrochemical detection and established the program of study into how dopamine transmission is governed in the brain. She joined the Department of Physiology, Anatomy and Genetics in 2006 to take up post as University Lecturer and Tutor for Medicine at Christ Church.
Prof. Simon Lewis, Associate Professor, Brain & Mind Research Institute, Sydney Medical School, Australia
Prof Simon Lewis undertook his neurology training in Cambridge and London before moving to Sydney in 2007, where he is curently NHMRC-ARC Dementia Fellow, who works as a Consultant Neurologist at the Royal Prince Alfred Hospital, and is Professor of Cognitive Neuroscience at the University of Sydney. He has a specialist interest in both newly diagnosed and advanced Parkinson's Disease with expertise in freezing of gait, hallucinations, memory problems and sleep disturbances. He is the Director of the Parkinson's Disease Research Clinic at the Brain & Mind Research Institute and heads the NSW Movement Disorders Brain Donor program. He has published over 100 peer review papers, two books and two book chapters and has attracted funding from the NHMRC, ARC and Michael J. Fox Foundation to support his research interests targeting quality of life in PD. In addition to this research, he previously sat on the Board of Parkinson's NSW. He recently led the nationwide 'DASH to the InfoLine' campaign aiming to raise awareness and reduce stigma in PD and headed the first trial to evaluate community based Parkinson's nurse specialists in Australia.
Pablo Martinez-Martin, MD, PhD, Instituto de Salud Carlos III, Madrid, Spain
Prof Pablo Martinez-Martin is a neurologist and a scientific researcher for the Spanish Public Boards of Research at the National Center of Epidemiology, Carlos II Institute of Health (ISCIII). He is also currently a member of the Consortium for Biomedical Research in Neurodegenerative Diseases in Madrid. He is a member of several Movement Disorder Society Task Forces for the revision of rating scales in Parkinson's disease, and international collaborative studies. Previously, he served as Scientific Director of the Research Unit for Alzheimer's Disease at the Alzheimer Center Reina Sofia Foundation, Head of the Section of Neuroepidemiology at the National Center of Epidemiology, and Head of the Department of Neurology at Hospital de Getafe and Central Red Cross Hospital. In addition, he was Associate Professor of Neurology at Complutense University in Madrid. His research interest is focused on movement disorders, especially Parkinson's disease, assessment instruments, outcomes research, dementia, prion diseases, and the burden placed on caregivers. He has published over 354 articles, 96 book chapters, and 17 books or monographies as editor or co-editor.
Andrew B. Singleton, Ph.D., NIH Distinguished Investigator, Laboratory of Neurogenetics, NIA, Bethesda, Maryland, USA
Dr. Andrew Singleton is a human geneticist whose research interests focus on the genetics of neurological disease. Dr. Singleton received his B.Sc. (Hons) degree from the University of Sunderland, UK and his Ph.D. from the University of Newcastle upon Tyne, UK where he studied genetic causes and contributors to dementia. Dr. Singleton performed his postdoctoral training at the Mayo Clinic in Jacksonville, Florida, and studied the genetic basis of neurological diseases such as dystonia, ataxia, essential tremor, dysautonomia, stroke and Parkinson's disease. In 2001, he joined the NIA as an Investigator within the newly created Laboratory of Neurogenetics. His laboratory works on the genetic basis of neurological disorders including Parkinson's disease, Alzheimer's disease, dystonia, ataxia, dementia with Lewy bodies, and amyotrophic lateral sclerosis. Dr. Singleton's group investigates the genetic and cellular mechanisms underlying simple-Mendelian and complex neurological diseases.The aim is to identify genetic variability that causes or contributes to disease and to use this knowledge to understand the molecular processes' underlying disease. He serves on the scientific advisory board of the Michael J. Fox Foundation among others, and has received various awards including the NIH Director's Award twice, and the American Academy of Neurology Movement Disorders Award for liftime acheivement in research in 2012.
Malú G. Tansey, PhD., Associate Professor of Physiology, Emory University School of Medicine, Atlanta, Georgia, USA
Prof Malú G. Tansey received her B.S./M.S. in Biological Sciences from Stanford University, and her PhD in cell regulation from UT Southwestern in Dallas, Texas. She completed her postdoctoral work in the Department of Molecular Pharmacology at Washington University, where she and her colleagues identified new members of the GDNF Family of Ligands. Since 2009, Tansey has served as Associate Professor of Physiology at Emory University, and before this was Assistant Professor of Physiology at UT Southwestern. Currently, the Tansey Laboratory in the Department of Physiology at Emory University's research interests include investigating the role and regulation of neuroinflammatory and immune system responses in modulating the gene-environment interactions that determine risk for development and progression of neurodegenerative and neuropsychiatric disease. Her lab employs molecular, cellular, biochemical, pharmacological, immunohistological, fixed and live-cell high-content imaging, and behavioral assays to address important mechanistic questions with the long-term goal of developing novel therapeutics for the prevention and/or treatment of chronic neurodegenerative and neuropsychiatric diseases characterized by chronic neuroinflammation.